A SIMPLE KEY FOR MKENA UNVEILED

CDER’s the latest proposal to withdraw the accelerated approval of Makena (HPC) was centered on a considerable randomized trial that failed to confirm the advantage of this drug to newborns or lower the risk of PTB. In creating the choice to suggest Makena’s withdrawal, CDER also reviewed final results from prior reports of progestins (HPC an